SCHEMBL6099863

SCHEMBL6099863

CCc1cccc(C(=O)O)c1-n1nnnc1C

nearest known ligand 0.45

Predicted protein targets (top 19)

geneUniProtsupporting neighboursconfidence
LMNA P02545 2/20 0.45
CLCN2 P51788 1/20 0.40
TP53 P04637 1/20 0.39
KCNN4 O15554 1/20 0.37
NR4A3 Q92570 1/20 0.37
MAPK1 P28482 3/20 0.36
ALDH1A1 P00352 5/20 0.35
TSHR P16473 2/20 0.35
HTT P42858 2/20 0.35
ALOX15 P16050 1/20 0.35
ELANE P08246 1/20 0.35
KDM4E B2RXH2 1/20 0.35
HPGD P15428 1/20 0.35
HSD17B10 Q99714 1/20 0.35
NPSR1 Q6W5P4 1/20 0.35
MEN1 O00255 1/20 0.34
KMT2A Q03164 1/20 0.34
IDH1 O75874 1/20 0.34
HMGB1 P09429 1/20 0.34

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL4563698 0.75 MYC (0.51) LMNAALDH1A1TSHRHTTALOX15
SCHEMBL21964199 0.72 CLCN2 (0.45) LMNACLCN2NR4A3ALDH1A1HTT
SCHEMBL3350879 0.71 MYC (0.57) LMNATP53ALDH1A1TSHRALOX15
SCHEMBL1493557 0.69 HSD11B1 (0.48) LMNATP53
Benzene SCHEMBL28861692 0.68 CLCN2 (0.54) LMNACLCN2ALDH1A1TSHRHTT
SCHEMBL22113414 0.68 ALDH1A1 (0.59) LMNAKCNN4MAPK1ALDH1A1TSHR
SCHEMBL622225 0.68 CLCN2 (0.54) LMNACLCN2ALDH1A1TSHRHTT
SCHEMBL1611340 0.68 POLB (0.59) TP53MAPK1ALDH1A1TSHRHPGD
SCHEMBL18983054 0.66 CLCN2 (0.56) LMNACLCN2NR4A3ALDH1A1TSHR
SCHEMBL578127 0.66 CLCN2 (0.56) CLCN2NR4A3ALDH1A1TSHRHTT

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 21 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-7026482-B2 Process for preparing imidazoquinolinamines MEDICIS PHARMACEUTICAL CORPORATION 2006-04-11 US disclosed
US-6897314-B2 Process for preparing imidazoquinolinamines 3M INNOVATIVE PROPERTIES COMPANY (US) 2005-05-24 US disclosed
US-20050096470-A1 Process for preparing imidazoquinolinamines 3M INNOVATIVE PROPERTIES COMPANY 2005-05-05 US disclosed
EP-0912565-B1 PROCESS FOR PREPARING IMIDAZOQUINOLINAMINES MINNESOTA MINING & MFG (US) 2004-04-14 EP disclosed
US-20040019213-A1 Process for preparing imidazoquinolinamines 3M INNOVATIVE PROPERTIES COMPANY 2004-01-29 US disclosed
US-6624305-B2 Reacting a 6H-imidazo(4,5-c) tetrazolo(1,5-a)quinoline with triphenylphosphine and hydrolyzing 3M INNOVATIVE PROPERTIES COMPANY 2003-09-23 US disclosed
US-6613902-B2 Induce biosynthesis of cytokines such as interferons, interleukins, and tumor necrosis factor in humans and in mice. 3M INNOVATIVE PROPERTIES COMPANY 2003-09-02 US disclosed
US-20030153762-A1 Process for preparing imidazoquinolinamines 3M INNOVATIVE PROPERTIES COMPANY 2003-08-14 US disclosed
US-20030130516-A1 PROCESS FOR PREPARING IMIDAZOQUINOLINAMINES 3M INNOVATIVE PROPERTIES COMPANY 2003-07-10 US disclosed
US-6534654-B2 Providing a tetrazole(1,5-a)quinolin-5-ol and nitrating the compound to form 4-nitrotetrazole(1,5-a)quinoline-5-ol, sulfonylating at 5-position, reacting with an amine to form a 5-amine derivative, further reducing to form 4,5-daimines 3M INNOVATIVE PROPERTIES COMPANY 2003-03-18 US disclosed
US-20020188127-A1 Process for preparing imidazoquinolinamines 3M INNOVATIVE PROPERTIES COMPANY 2002-12-12 US disclosed
US-6437131-B1 REACTING A 6H-IMIDAZO(4,5-C)TETRAZOLO(1,5-A)QUINOLINE WITH TRIPHENYLPHOSPHINE, HYDROLYZING TO FORM 1H-IMIDAZO(4,5-C) QUINOLIN-4-AMINES; INTERMEDIATE IS A 4-NITROTETRAZOLO(1,5-A) QUINOLIN-5-SULFONATE IN THE PR 3M INNOVATIVE PROPERTIES COMPANY 2002-08-20 US disclosed
US-6150523-A Process for preparing imidazoquinolinamines 3M INNOVATIVE PROPERTIES COMPANY (US) 2000-11-21 US disclosed
US-5998619-A Process for preparing imidazoquinolinamines 3M INNOVATIVE PROPERTIES COMPANY (US) 1999-12-07 US disclosed
EP-0912565-A1 PROCESS FOR PREPARING IMIDAZOQUINOLINAMINES MINNESOTA MINING AND MANUFACTURING COMPANY (US) 1999-05-06 EP disclosed
EP-0912564-A1 PROCESS FOR PREPARING TETRAHYDROIMIDAZOQUINOLINAMINES MINNESOTA MINING AND MANUFACTURING COMPANY (US) 1999-05-06 EP disclosed
US-5741908-A Process for reparing imidazoquinolinamines MINNESOTA MINING AND MANUFACTURING COMPANY (US) 1998-04-21 US disclosed
WO-1997048703-A1 PROCESS FOR PREPARING TETRAHYDROIMIDAZOQUINOLINAMINES MINNESOTA MINING AND MANUFACTURING COMPANY (US) 1997-12-24 WO disclosed
WO-1997048704-A1 PROCESS FOR PREPARING IMIDAZOQUINOLINAMINES MINNESOTA MINING AND MANUFACTURING COMPANY (US) 1997-12-24 WO disclosed
US-5693811-A Process for preparing tetrahdroimidazoquinolinamines MINNESOTA MINING AND MANUFACTURING COMPANY (US) 1997-12-02 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20040019213-A1 Process for preparing imidazoquinolinamines VAT1, QARS1, TALDO1 LMNA 1618/4885CLCN2 3891/4885TP53 3190/4885
US-20050096470-A1 Process for preparing imidazoquinolinamines ITPA, INMT, PIP4K2C LMNA 1093/4885CLCN2 4473/4885TP53 2744/4885
US-20020188127-A1 Process for preparing imidazoquinolinamines VAT1, QARS1, TALDO1 LMNA 1618/4885CLCN2 3891/4885TP53 3190/4885
US-20030130516-A1 PROCESS FOR PREPARING IMIDAZOQUINOLINAMINES VAT1, QARS1, TALDO1 LMNA 1618/4885CLCN2 3891/4885TP53 3190/4885
US-20030153762-A1 Process for preparing imidazoquinolinamines VAT1, QARS1, TALDO1 LMNA 1618/4885CLCN2 3891/4885TP53 3190/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.